Figure 10.

Psoriatic arthritis: improvement of joint symptoms. Infliximab significantly improves joint symptoms compared with placebo (P <0.001 at week 16) in the IMPACT 1 study (n = 104 patients) [82]. (a) Prior to crossover. (b) Open-label extension, up to 54 weeks. ACR, American College of Radiology.

Smolen and Emery Arthritis Research & Therapy 2011 13(Suppl 1):S2   doi:10.1186/1478-6354-13-S1-S2